Velg din region

Velg regionen som passer best for din plassering eller dine preferanser.

International

Velg ditt nettstedsspråk

Denne innstillingen kontrollerer språket for brukergrensesnittet, inkludert knapper, menyer og all tekst på nettstedet. Velg ditt foretrukne språk for best brukeropplevelse.

Velg språk for stillingsannonser

Velg språkene for stillingsannonser du vil se. Denne innstillingen bestemmer hvilke stillingsannonser som vises for deg.

Pieris Pharmaceuticals GmbH

Freising, Tyskland

Besøk nettside

Om arbeidsgiveren

Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin^® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.

Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.

Pieris has a diverse pipeline of Anticalin Therapeutics for a number of different indications and has active, multi-program R&D collaborations with Roche, Daiichi Sankyo, the Sanofi Group, Zydus Cadila and Stelis Biopharma.

Pieris, founded in 2001, was funded by premier biotechnology-focused venture capital firms including OrbiMed Advisors as its lead investor as well as Forbion Capital, Gilde Healthcare Partners, Novo Nordisk Ventures, Global Life Science Ventures, BayTech Venture Capital, Bio-M, TCB, KfW and BayernKapital.

Pieris has become a publicly traded company on December 18, 2014 (NASDAQ:PIRS).